A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

• Aaron D. Schimmer ,

  * E-mail: aaron.schimmer@utoronto.ca

  Affiliation Princess Margaret Cancer Centre, Toronto, Ontario, Canada

  ⨯
• Azra Raza,

  Affiliation Columbia University Medical Center, New York, New York, United States of America

  ⨯
• Thomas H. Carter,

  Affiliation The University of Iowa, Iowa City, Iowa, United States of America

  ⨯
• David Claxton,

  Affiliation Penn State, Hershey, Pennsylvania, United States of America

  ⨯
• Harry Erba,

  Affiliation University of Alabama at Birmingham, Birmingham, Alabama, United States of America

  ⨯
• Daniel J. DeAngelo,

  Affiliation Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Martin S. Tallman,

  Affiliation Leukemia Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, New York, United States of America

  ⨯
• Carolyn Goard,

  Affiliation Princess Margaret Cancer Centre, Toronto, Ontario, Canada

  ⨯
• Gautam Borthakur

  Affiliation The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯